相关实验视频
Updated: Aug 12, 2026

10:37
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
血小板糖蛋白IIIa多态性和冠状动脉支架血栓形成的风险
D H Walter1, V Schächinger, M Elsner
1Department of Internal Medicine IV, University of Frankfurt, Germany.
Lancet (London, England)
|July 4, 1998
概括
PIA2基因变异增加了冠状动脉支架血栓形成的风险. 这一发现表明,个性化抗血小板治疗可能对患有这种遗传标记物的患者有益.
科学领域:
- 心血管医学 心血管医学
- 遗传学 是一个遗传学.
- 血栓形成研究研究
背景情况:
- 冠状动脉支架有效治疗冠状动脉狭窄症,但存在支架血栓形成的风险.
- 血小板聚合是发展支架血栓的关键因素.
- 这项研究调查了特定的血小板糖蛋白IIIa基因多态性 (PIA2) 与冠状动脉支架血栓形成风险之间的关联.
研究的目的:
- 确定血小板糖蛋白IIIa基因的PIA2等位基因是否与冠状动脉支架血栓形成的风险增加有关.
- 在接受冠状动脉支架插入的患者中确定支架血栓形成的遗传预测因子.
主要方法:
- 一项前性研究跟踪了冠状动脉支架插入后的318名患者30天.
- 用聚合酶链反应 (PCR) 和凝电泳来识别PIA1和PIA2等位基因.
- 后勤回归分析计算了支架封闭的几率比,评估与PIA2等位基因相关的相对风险.
主要成果:
- 在19.8%的患者中存在PIA2等位基因;80.2%的患者是PIA1.1的同位基因.
- 支架血管封闭发生在9.5%的PIA2等位基因患者中,而PIA1同卵性患者中为1.9%.
- 多变量分析确定了PIA1/A2基因型作为支架血栓形成的唯一重要的独立预测因子 (几率比5.26).
结论:
- 携带PIA2等位基因的患者面临着显著更高的冠状动脉支架血栓形成风险.
- 这种遗传倾向可能会引导使用糖蛋白IIb/IIIa抑制剂进行抗血小板治疗.
- 应考虑使用糖蛋白IIb/IIIa抑制剂可能增加的出血并发症.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

